What is SION's additional paid-in capital?

SION (SION) reported additional paid-in capital of $571.38M in Q1 2026.

How has SION's additional paid-in capital changed year-over-year?

SION's additional paid-in capital increased by 4.1% year-over-year, from $548.99M to $571.38M.

What does additional paid-in capital mean?

Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.

SION SION Additional Paid-In Capital

Additional Paid-In Capital at other companies

Septerna, Inc.SEPN

$554.87M+2.8%

BioCryst PharmaceuticalsBCRX

$1.67B+27.2%

Denali Therapeutics Inc.DNLI

$3.1B+11.3%

Neurocrine BiosciencesNBIX

$2.82B+11.3%

Other financials

Income statement

See full

Operating income-$29.6M-50.6%

Net income-$26.8M-62.5%

EPS (diluted)-$0.60+3.2%

Balance sheet

See full

Cash & equivalents$64.3M-23.2%

Total debt$8.4M-11.8%

Total equity$288.2M-18.1%

Total assets$305.0M-17.5%

Cash flow

See full

Operating cash flow-$21.8M-34.1%

CapEx--100%

Free cash flow-$21.8M-33.4%

Valuation

See full

Market cap$1.86B—

Returns & leverage

See full

Return on equity-26.7%—

Debt / equity0×0.0×

Current ratio22.6×-6.1×

Where this comes from

Reported directly by SION in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: SION’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SION's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is SION's additional paid-in capital?: SION (SION) reported additional paid-in capital of $571.38M in Q1 2026.
How has SION's additional paid-in capital changed year-over-year?: SION's additional paid-in capital increased by 4.1% year-over-year, from $548.99M to $571.38M.
What does additional paid-in capital mean?: Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.